Effects of high thoracic epidural anesthesia on mixed venous oxygen saturation in coronary artery bypass grafting surgery

Ercan Gurses
Derviş Berk
Hülya Sungurtekin
Aslı Mete
Simay Serin

Corresponding Author:
Ercan Gürses, e-mail: elgurses@gmail.com

Source of support:
The present study was funded solely by the institution of the authors

Background: To investigate possible effects of high thoracic epidural anesthesia (HTEA) on mixed venous oxygen saturation (SvO₂) in coronary artery bypass grafting surgery (CABGS).

Material/Methods: Sixty-four patients scheduled for CABGS were randomly assigned to either test (HTEA) or control group. Standard balanced general anesthesia was applied in both groups. Mean arterial blood pressure (MAP), heart rate (HR), oxygen saturation (SpO₂), central venous pressure (CVP), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), pulmonary compliance (C), bispectral index (BIS), body temperature, SvO₂, hematocrit values were recorded before induction. Postoperative hemodynamic changes, inotropic agent, need for vasodilatation, transfusion and additional analgesics, recovery score, extubation time, visual analogue scale (VAS) values, duration of stay in intensive care unit (ICU) and hospital were recorded.

Results: Study groups were similar in SpO₂, CVP, PCWP, PAP, C, body temperature, BIS values, development of intraprocedural bradycardia. In HTEA group, intraoperative MAP, SVR, PVR, need for transfusion were lower, whereas CO, CI, SvO₂, hematocrit values were higher (p<0.05). Postoperative MAP, HR, hypertension development, need for vasodilator, transfusion, analgesics, extubation time, recovery data, duration of stay in ICU, hospital were lower in HTEA group (p<0.05). VAS score decreased in 30 minutes and 12 hours following extubation in HTEA and control group, respectively.

Conclusions: HTEA may improve balance between oxygen presentation and usage by suppressing neuroendcrin stress response; provide efficient postoperative analgesia, more stabile hemodynamic, respiratory conditions, lower duration of stay in ICU, hospital.

Key words: coronary arteries bypass grafting surgery • mixed venous oxygen saturation • thoracic epidural anesthesia

Full-text PDF: http://www.medscimonit.com/download/index/idArt/883861
Background

It is quite well known that increased metabolism during and after coronary artery bypass grafting surgery (CABGS), impaired immune response and hemodynamic, respiratory and thromboembolic complications are mostly due to the unsuppressed neuroendocrin stress response [1–6]. Sympathetic activity leading to hypertension, tachycardia and increased metabolism impairs platelet activation and peripheral blood flow on the one hand and impairs peripheral oxygen saturation on the other which leads to paradox ischemia despite the high Fio\textsubscript{2} level. Therefore, it is critical to determine the balance between oxygen delivery (DO\textsubscript{2}) and consumption (VO\textsubscript{2}) in CABGS [4,7].

Mixed venous oxygen saturation is an important parameter in determining general tissue oxygen balance. It is closely related with the arterial oxygen content and cardiac output. Mixed venous oxygen saturation (SvO\textsubscript{2}) has been suggested to be more sensitive than the hemodynamic parameters to indicate early findings of sympathetic activity [8].

Respiratory complications are mainly due to patient’s inability to use the protective mechanisms such as cough, deep breath and sigh which arise from not only the pump lung but also insufficient pain control [9]. Improvement in postoperative diaphragm and respiratory functions has been reported with high thoracic epidural anesthesia (HTEA) [10,11]. Compliance (C) is a widely-used parameter in anesthetized or mechanically ventilated patients in intensive care unit (ICU) to evaluate respiratory functions [12]. It has been reported that HTEA suppresses mediator release, significantly decreases need for analgesics, minimizes respiratory complications by perfect postoperative pain control eventually enabling early extubation and discharge from intensive care unit [1,13–15].

Possible effects of HTEA in patients with coronary artery diseases have not been clarified, yet. Therefore, the present study was planned to investigate likely influences of HTEA on SvO\textsubscript{2}, hemodynamic and respiratory parameters in CABGS.

Material and Methods

This prospective, randomized and controlled study was conducted with ethical principles, including the World Medical Association’s Declaration of Helsinki, as revised in 2008. The study was approved by the Ethics Committee of the Medical School, Pamukkale University. Written informed consent was received from each individual before their entry to the study. A total of 64 patients were included in the study between July 2010 and January 2011 (Figure 1).

All patients were scheduled for CABS in elective conditions with ASA II-III. There were 46 male and 18 female patients with an age range of 40–79 years. Exclusion criteria were; hypersensitivity towards any of the chemicals to be used, contraindication of epidural anesthesia (dermal infections, nervous system diseases, severe hypovolemia, high intracranial pressure, severe aorta stenosis, severe mitral stenosis etc.), patients with a history of vertebral surgery, cervical or thoracic vertebra arthritis, morbid obesity (BMI >35), coagulopathy, <40% ejection fraction (EF) and preoperative inotropic agent usage.

Figure 1. Consort diagram.
Patients were randomly assigned to the study groups by the closed envelope method. Pain during the postoperative follow-up period was assessed on a 10 cm visual analogue scale (VAS) anchored by verbal descriptors, “no pain” and “worst imaginable pain”. Forms were given to all patients on the day of operation and they were asked to thick the value of pain at the end of each day.

Following venous access in the operation room, DII-V5 ECG, SpO2, nasopharyngeal body temperature, BIS and invasive arterial blood pressure were monitored with Datex Ohmeda Cardiocap V. Invasive arterial blood pressure monitoring was done after radial artery cannulation with standard 20 gauge arterial cannula (BD Arterial Cannula, BD Critical Care Systems Pte Ltd., 198 Yishun Ave 7, Singapore). After local anesthesia under asetic conditions with 2% lidocaine (Jetmonal 2% ampoule, Adeka Drug Ltd., Samsun, Turkey), a pulmonary arterial catheter (7.5 F REF: 774HF75 Edwards Lifesciences LLC, USA) was placed through the right internal jugular vein with a single lumen sheath (8.5 F REF: I351BF85H Edwards Lifesciences LLC, Irvine, CA, USA). First measurements were performed after calibration of the instrument.

Anesthesia was induced as follows; preoxygenation with 100% oxygen for 1 min, 3–5 mg/kg thiopentale (Pental Sodium 1 gr flacon, İ.E. ULAGAY, Istanbul, Turkey) and 0.6 mg/kg rocuronium bromure (Esmeron 50 mg/5 ml flacon, N.V. Organon, Oss, Holland) intravenous bolus. Maintenance of anesthesia was provided with sevofothane (Sevorane 250 ml solution, Abbott Laboratories Ltd., Istanbul, Turkey) in the mixture of 50% O2 and 50% dry air to preserve BIS in the range of 40–50 and 0.5 µg/kg/min remifentanil hydrochloror (Ultiva 2 mg flacon, GlaxoSmithKline Ltd., Istanbul, Turkey) infusion and with 0.15 mg/kg rocuronium bromur injection when required.

The patients were given lateral decubitis position in the HTEA group following anesthesia induction, intubation and achievement of hemodynamic stability. Under sterile conditions, epidural catheter (Braun Perifix 20 G) was placed at C6-C7 level at least 1 hour prior to heparin injection. Catheter was moved caudaely 3–4 cm and fixed to the skin approximately at the level of T2-T4. After this induction, 0.075 mg/kg levobupivacaine hydrochloror (Chirocaine 5 mg/ml Abbott Lab., Istanbul, Turkey) and 0.01 mg/kg fentanyl (Fentanyl citrate, 50 µg/ml, Abbott Lab., Istanbul, Turkey) in total 10 ml bolus was given and 0.0375 mg/kg/h levobupivacaine + 0.5 µg/kg/h fentanyl epidural infusion was started with patient-controlled analgesia instrument (Abbott Pain Management Provider, Abbott Laboratoires, North Chicago IL, USA).

Blood pressure values as well as CVP, CO, CI, PVR, SVR, PCWP, PAP, SpO2, body temperature and BIS values were recorded by CO monitor (Vigilance CO Monitor, REF: VGS2V, Edwards Lifesciences LLC, Irvine, CA, USA) in all patients before and after induction (before and after opening up the sternum) and after CPB (before and after the closure of sternum). SvO2 values were recorded before induction and also 5, 10, 15, 20, 40, 60-min after induction and 5, 10, 15, 20, 40, 60-min after CPB. Pulmonary compliance was determined in the study groups; after induction before opening the sternum, after ending CPB and closing the sternum, and during the postoperative follow-up (30-min, 1-hour, 2-hour, 4-hour and before extubation). Intraoperative hypotension or hypertension, development of bradycardia and disrythmia, need for vasopressor or vasodilatator and transfusion were also recorded.

All patients were taken to the coronary surgery ICU in the postoperative period, monitored and mechanically ventilated. ECG, HR, SpO2, body temperature, MAP, CVP and pulmonary compliance were determined by Avea mechanical ventilator (Viasys Respiratory Care Inc. 1100 Bird Centre Drive, Palm Springs, CA, USA) on 30-min, 1-hour, 2-hour, 4-hour and before extubation. Epidural infusion was continued during the patients’ stay in ICU.

Intramuscular diclofenac sodium (Dikloron 75 mg 10 amp, Mefar Drug Ltd., Istanbul, Turkey) was injected as the analgic agent in the control group. Analgesia was evaluated by asking patients to record VAS on 30-min, 1-hour, 2, 4, 8, 12, and 24 hours following extubation.

In case of hypotension (OAB <50 mmHg) development in ICU, crystalloid, colloid liquid, and efedrin (Efedrin 50 mg/ml amp, Osel Drug Ltd., Istanbul, Turkey) was given respectively. It was planned to administer 2.5–10 mg intravenous bolus and adrenalin (Adrenalin Biofarma 1 mg/ml ampul, Biofarma Drug Ltd., Istanbul, Turkey) with 0.05–1 mg intravenous bolus. In case of bradycardia, atropine (Atropin Sulphate 1 mg/ml, Biofarma Drug Ltd., Istanbul, Turkey) was given respectively. Patients were extubated when they completely recover and regain muscular power (if the Aldrete’s recovery score is 9, PaCO2 <45 mmHg, PaO2 >100 mmHg FiO2 0.4 and pH is between 7.35–7.45 together with stabile hemodynamic and metabolic parameters) and VAS was recorded after extubation. Need for additional analogesics, recovery score, duration of stay in ICU and hospital were all recorded in the two study groups.

**Statistical analysis**

The primary outcome measure was mixed venous oxygen saturation. An a priori power analysis based on the previously published data suggested that a minimum of 32 patients were needed to provide 80% power to detect a difference in the primary endpoint of changes in SvO2.
Table 1. Demographic and operative data of study groups (mean ± standard deviation).

|                        | HTEA          | Control       |
|------------------------|---------------|---------------|
| Age (years)            | 62.8±10.5     | 61.7±8.8      |
| Weight (kg)            | 75.6±12.1     | 75.6±9.2      |
| Height (cm)            | 167.5±8       | 168.5±6.8     |
| BMI                    | 26.9±3.9      | 26.7±3.4      |
| BSA (m²)               | 1.85±0.2      | 1.99±0.1      |
| NYHA II/III            | 8/24          | 7/25          |
| CPB Time (min)         | 137.7±54.1    | 134.9±44.2    |
| EF (%)                 | 49.4±11       | 51.3±11       |
| Operation Time (min)   | 328.2±12.7    | 325.8±12.3    |
| Number of Anastomoses  | 3.3±0.7       | 3.6±0.7       |
| ASA II/III             | 8/24          | 7/25          |
| Female/Male            | 8/24          | 10/22         |

There were no significant differences between the study groups in demographic or operative data (p>0.05) in each group would be required to detect a 15% increase in mixed venous oxygen saturation, with a power of 90% at the 0.05 level of significance.

A statistical software program (SPSS 16.0 for Windows, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Qualitative parameters were compared between the study groups by Chi-Square and Fisher Exact tests. Numerical variables were compared by independent samples t test. Intragroup comparisons were made by repeated measures ANOVA test and Bonferroni Post-hoc test. All tests were performed at a=0.05 significance level.

Results

The study groups were similar in terms of demographic variables (Table 1). Data about MAP, HR, CO, CI, SVR, PVR and C were presented in Table 2. Before induction, MAP was similar in the study groups, but it was significantly lower in the HTEA group after the opening of sternum, before the closure of sternum (p<0.05). There was no significant difference between the groups after the closure of sternum and the data was within normal ranges. There are significant differences between the recordings before and after induction (p<0.05) (Table 2). Intraoperative HR and SpO₂ values were similar in the study groups. CO, CI and SVR were similar in the study groups before induction, but after induction CO and CI were significantly higher and SVR was significantly lower in the HTEA group (p<0.05) (Table 2).

Pulmonary compliance values were higher in the HTEA group after the closure of sternum, but there was no significant difference between the study groups. Intragroup comparisons in the control group indicated that the recordings decreased significantly after the closure of sternum compared to those before induction (p<0.05) (Table 2). PVR and SVR were similar in the study groups before induction, but they were lower in the HTEA group after induction (p<0.05) (Table 2). CVP, PCWP, PAP were all within normal ranges and similar in the study groups at all recording time points (Table 2).

There was no significant difference in SvO₂ between values before and after induction, but it started to increase in the HTEA group at 10 min and stayed high until 60 min after CPB (p<0.05) (Table 3).

Hematocrit values before induction were 35.2±4.6% and 33.5±5.3% in the HTEA and control groups, respectively. At 5 min after CPB it was 31.4±4.6% and 28.2±4.1% in the HTEA and control groups, respectively (p<0.05). At 60-min after CPB it was 32±4.5% and 27.8±4.2% in the HTEA and control groups, respectively (p<0.05). Hematocrit values decreased significantly in the control group compared to the HTEA group (p<0.05).

Intraoperative complications such as hypotension (13–22%), dysrhythmia (12.5–16%), need for inotropic agent after CPB (15.6–22%) were all lower in the HTEA group, but there was no significant difference between the groups. There was significantly less need in the HTEA group than the control group for transfusion after CPB (56–84%) before the patient is transferred to ICU (p<0.01). Mean arterial blood pressure and heart rate were higher in the control group after the patients’ transfer to ICU (p<0.05). Intergroup and intragroup comparisons revealed similar and within normal range recordings of postoperative SpO₂, CVP and compliance (p<0.05) (Table 4). Development of postoperative hypertension was significantly higher in the control group (p<0.001). There were no significant differences in the frequencies of postoperative dysrhythmia, bradycardia, hypotension need for inotropic agents. Vasodilator agents and additional analgesics were more frequently needed in the control group during the ICU stay (p<0.001). Transfusion requirement was significantly less in the HTEA group (p<0.05), as less than 30% of patients in this group required transfusion. Recovery scores were less in the HTEA group (p<0.001). Extubation time, stay in ICU and stay in hospital were all shorter in the HTEA group (p<0.001) (Table 5).

Intergroup comparisons with regard to VAS indicated that the scores at 30 min, 1, 2, 4 and 8 hours were all less in the HTEA...
High thoracic epidural anesthesia and mixed venous oxygen saturation © Med Sci Monit, 2013; 19: 222-229

Table 2. Intraoperative hemodynamic and respiratory parameters (mean ±SD).

|                  | Before induction | Before opening of sternum | After opening of sternum | Before closure of sternum | After closure of sternum | p* |
|------------------|------------------|---------------------------|--------------------------|--------------------------|--------------------------|----|
| MAP (mmHg)       |                  |                           |                          |                          |                          |    |
| HTEA             | 84.6±12.3        | 71.8±10.4                 | 67.9±9.5                 | 68.1±6.9                 | 72.6±6.3                 | <0.05 |
| Control          | 86.8±11.7        | 80.2±10.1                 | 75.8±7.7                 | 74.2±8.6                 | 73.3±8.9                 | <0.05 |
| p**              | >0.05            | <0.05                     | <0.05                    | <0.05                    | >0.05                    |    |
| HR (beat/min)    |                  |                           |                          |                          |                          |    |
| HTEA             | 79.6±8.3         | 72.6±6.7                  | 70.9±6.6                 | 73.5±6.6                 | 73.3±6.6                 | <0.05 |
| Control          | 77±18.1          | 72.8±7.8                  | 69.4±4.7                 | 72.3±6.5                 | 72.6±7.7                 | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| SpO2 (%)         |                  |                           |                          |                          |                          |    |
| HTEA             | 97.8±1.3         | 98.8±0.9                  | 98.9±0.9                 | 99.0±0.9                 | 98.8±0.9                 | >0.05 |
| Control          | 97.4±2.2         | 98.9±1.4                  | 99±1.5                   | 98.5±2.2                 | 98.3±1.1                 | >0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| CO (l/min)       |                  |                           |                          |                          |                          |    |
| HTEA             | 6±0.6            | 6.2±0.7                   | 6.3±0.7                  | 6.1±0.7                  | 6±0.7                    | >0.05 |
| Control          | 5.9±0.7          | 5.2±0.6                   | 5.3±0.9                  | 5.1±0.8                  | 5±0.7                    | <0.05 |
| p**              | >0.05            | <0.05                     | <0.05                    | <0.05                    | <0.05                    |    |
| CI (l/min/m²)    |                  |                           |                          |                          |                          |    |
| HTEA             | 3.2±0.4          | 3.3±0.4                   | 3.4±0.5                  | 3.3±0.5                  | 3.2±0.5                  | >0.05 |
| Control          | 3.1±0.5          | 2.8±0.4                   | 2.8±0.5                  | 2.7±0.4                  | 2.6±0.4                  | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| SVR (din.sec/cm²) |                 |                           |                          |                          |                          |    |
| HTEA             | 1052±214         | 817±200                   | 736±199                  | 767±191                  | 871±186                  | <0.05 |
| Control          | 1092±222         | 1086±228                  | 981±258                  | 1019±239                 | 1063±299                 | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| PVR (din.sec/cm²) |                 |                           |                          |                          |                          |    |
| HTEA             | 89.2±23          | 69.5±21                   | 67.8±26                  | 68.5±24                  | 67.1±23                  | <0.05 |
| Control          | 92.1±26          | 91.5±26                   | 95.5±27                  | 91.6±20                  | 90.9±24                  | >0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| C (ml/cmH₂O)     |                  |                           |                          |                          |                          |    |
| HTEA             | 52±8.8           | 52±8.9                    | 52±8.9                   | 52±9.7                   | 51.8±8.9                 | >0.05 |
| Control          | 52.9±8.9         | 51.8±9                    | 50.6±10                  | 46.7±9                   |                     >0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| CVP (cmH₂O)      |                  |                           |                          |                          |                          |    |
| HTEA             | 10.4±3.4         | 10±3.3                    | 11.2±3.6                 | 10.5±3.2                 | 9.2±3.4                  | <0.05 |
| Control          | 11.3±4.2         | 11.2±3.3                  | 12.7±4.1                 | 10.9±3.8                 | 9.6±4.1                  | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| PCWP (mmHg)      |                  |                           |                          |                          |                          |    |
| HTEA             | 15.6±3.6         | 16.4±4.8                  | 15.9±3.7                 | 13.9±3.6                 | 13.7±3.5                 | <0.05 |
| Control          | 15.6±3.6         | 15.1±3.6                  | 14.6±3.2                 | 13.2±2.3                 | 12.4±2.6                 | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |
| PAP (mmHg)       |                  |                           |                          |                          |                          |    |
| HTEA             | 22.4±4.9         | 21.6±4.5                  | 21±4.2                   | 19±4                     | 18.3±3.4                 | <0.05 |
| Control          | 22.7±4.5         | 21.2±4                    | 21±3.9                   | 18±2.5                   | 18±2.6                   | <0.05 |
| p**              | >0.05            | >0.05                     | >0.05                    | >0.05                    | >0.05                    |    |

* Indicates statistical analyses of serial evaluation in each group; ** indicates statistical analyses of two groups.

The risk for spinal hematoma due to the heparinisation, haemodilution and coagulation factors limit the usage of HTEA in open cardiac surgeries [20,21]. Goldstein et al. [13] gave heparin at least 1 h after placement of epidural catheter and reported no neurological complications in patients with normal coagulation test results who are not on anticoagulation therapy. Accordingly, systemic anticoagulation was applied at least 1 h after placement of epidural catheter in the present study and our findings are similar as no complications were detected.

Discussion

Surgery stress, insufficient pain control, hypercoagulability, release of proinflammatory cytokines, and activation of neuroendocrine system are among the major factors determining postoperative morbidity [16,17]. HTEA improves the balance between oxygen presentation and usage in ischemic myocardium via selective blockade of cardiac sympathetic innervation (T1-T5) [11,17]. Thoracic epidural anesthesia decreases myocardial infarcts by 40% and protects lung functions during the postoperative 24 hours [18,19].

The group approached to that of the HTEA group only at hour-12.
In patients undergoing CABGS, the transient sympathetic blockage provided by HTEA has been reported to decrease perioperative myocardial ischemia, regulate coronary perfusion, and significantly improve functions of left ventricle [14,22–24]. Mendez-Tellez [25] stated that intrathoracic blood volume, PVR and hypoxic pulmonary vasoconstrictor response may be induced by the change in pulmonary vascular tonus due to the sympathetic disinnervation, and HTEA may reduce PVR through the vasodilatation in pulmonary blood vessels. Accordingly, we found similar intraoperative SpO\textsubscript{2}, CVP, PCWP, PAP and C in the study groups, whereas in the HTEA group MAP, HR, SVR and PVR measurements and intraoperative hypotension, disrhythmia development, need for

### Table 3. Intraoperative SVO\textsubscript{2} values in the study groups (mean ± SD).

| SVO\textsubscript{2} (%) | HTEA       | Control     | P*          |
|--------------------------|------------|-------------|-------------|
| Before anesthesia induction | 69±6.8   | 67±6.9        | >0.05       |
| After anesthesia induction | 68.4±7.1 | 65.7±7.2      | <0.05       |
| After epidural Bolus, 5.min | 70.6±7.8 | 68±8.5       | <0.05       |
| After epidural Bolus, 10.min | 71.3±6.4 | 63.2±6.6      | <0.05       |
| After epidural Bolus, 15.min | 75.9±8.9 | 64.4±5.9      | <0.05       |
| After epidural Bolus, 20.min | 74.6±7.2 | 62.6±9.7      | <0.05       |
| After epidural Bolus, 40.min | 77.5±9.7 | 69.4±7.9      | <0.05       |
| After epidural Bolus, 60.min | 81.7±10.4 | 65.2±10.1    | <0.05       |
| After CPB, 5 min            | 82.4±9.2 | 68.8±8.6      | <0.05       |
| After CPB, 10.min           | 79.9±9.7 | 65.2±10.1     | <0.05       |
| After CPB, 15.min           | 84.1±11.0 | 66.6±7.7    | <0.05       |
| After CPB, 20.min           | 84.2±10.8 | 67.9±4.5     | <0.05       |
| After CPB, 40.min           | 84.9±12.1 | 67.7±8.8      | <0.05       |
| After CPB, 60.min           | 86.1±9.7 | 67.9±10.1     | <0.05       |

* Indicates statistical analyses of serial evaluation in each group; ** indicates statistical analyses of two groups.

### Table 4. Postoperative MAP, HR, SpO2, CVP and C values (mean±SD).

|                | Min-30 | Hour-1 | Hour-2 | Hour-4 | Pre-extubation | P*          |
|----------------|--------|--------|--------|--------|----------------|-------------|
| MAP (mmHg)     | HTEA   | 71.9±13.4 | 72.1±14 | 75±12   | 75.8±11.4 | 73.1±14.5 | <0.05       |
| Control        | 74.5±12.7 | 84.8±13.4 | 83.2±12.5 | 86.2±12 | 86.3±13  | <0.05       |
| HR (beat/min)  | HTEA   | 77±10.6 | 76.8±9.3 | 77.6±8.6 | 78.1±9.4 | 78±11.4  | >0.05       |
| Control        | 83.5±9.2 | 84.3±11  | 85.4±10.5 | 83±11.3 | 83.7±10.6 | >0.05       |
| SpO2 (%)       | HTEA   | 98.7±0.8 | 98.5±0.6 | 98.7±0.5 | 98.6±0.6 | 98.9±0.6 | >0.05       |
| Control        | 98.6±1  | 98.7±0.9 | 98.7±0.7 | 98.5±0.8 | 98.5±0.8 | >0.05       |
| CVP (mmHg)     | HTEA   | 8.9±2.2 | 9±2.3   | 8.6±2.1 | 9±1.8    | 9.2±1.7  | >0.05       |
| Control        | 9.4±2.7 | 9.1±2.3 | 9±2     | 8.7±2   | 8.9±1.4  | >0.05       |
| C (mL/cmH\textsubscript{2}O) | HTEA   | 51.5±6.9 | 52.3±6.3 | 52.4±6.3 | 52.2±6   | 53.6±6.5 | >0.05       |
| Control        | 49.2±9.6 | 49.7±1.7 | 49.9±7.2 | 50.7±6.9 | 51±7.3   | >0.05       |

* Indicates statistical analyses of serial evaluation in each group; ** indicates statistical analyses of two groups.
Clinical Research

High thoracic epidural anesthesia and mixed venous oxygen saturation

© Med Sci Monit, 2013; 19: 222-229

Table 5. Postoperative complications in the study groups (N and%) and (Mean ±SD).

|               | Control | HTEA |
|---------------|---------|------|
|               | N %     | N %  |
| Hypotension   | 4 13    | 5 16 |
| Hypertension* | 15 47   | 2 6.2|
| Bradycardia   | 1 3.1   | 2 6.2|
| Dysrhythmia   | 3 9.3   | 3 9.3|
| Need for inotrop* | 7 22 | 6 19 |
| Need for additional analgesics* | 15 47 | 2 6.2|
| Transfusion 0** | 11 34 | 22 69|
| Transfusion 1** | 15 47 | 6 19 |
| Transfusion 2** | 4 13 | 2 6.2|
| Mean ±SD      | 4.7±1.9 | 2.9±1.8|
|               | 6.8±2   | 4.1±1.7|
|               | 3.6±1.8 | 1.5±1.6|
|               | 8.8±1.7 | 4.9±1.5|

* p<0.001; ** p<0.05.

inotropic and transfusion were all less and CO, CI, SvO₂, and Htc measurements were higher than the control group.

Kessler et al. [14] have placed the thoracic epidural catheter at T1-T2 or T2-T3 level, while Fillinger et al. [24] placed it between the T1 and T10 levels in a cranial direction. In the present study, we placed the thoracic epidural catheter at the C6-C7 level in a caudal direction. We think this application provided stable MAP and HR in the HTEA group through the direct blockage of cardiac sympathetic nerves. The level of CO changes inversely with the change in systemic vascular resistance when the arterial pressure is stable. Therefore, the increase observed in the CO and CI levels in the present HTEA group may be explained by the decrease in SVR.

The amount of oxygen presentation to tissues may be indirectly evaluated by the changes in DO₂ and VO₂. Mixed venous oxygen saturation is a marker of the balance between whole body DO₂ and VO₂. SvO₂ shows a positive correlation with CO, Htc and SaO₂, together with a negative correlation with VO₂. Therefore, continuous monitoring of SvO₂ enables simultaneous monitoring of these four parameters. Normally, peripheral VO₂ is independent from DO₂. When CO and DO₂ decrease, peripheral O₂ extraction increases to keep VO₂ stable and as a result SvO₂ decreases. Sepsis on the other hand, decreases peripheral O₂ usage and thereby increases SvO₂ [12]. Lorentzen et al. [8] reported that Cl, Htc, SpO₂, aortic valve surgery, vasodilatation treatment and VO₂ are the factors affecting SvO₂; they result in low SpO₂, Htc or Cl, increased peripheral VO₂ during recovery as well as affecting veins. The present findings revealed increased intraoperative SvO₂ values in the HTEA group compared to the control group after the epidural injection. HTEA decreased usage of oxygen significantly leading to an increase in SvO₂ measurements. These findings may be explained by the suppressive effect of HTEA on sympathetico-neuroendocrin stress response. Moreover, hypotension development was significantly less in the HTEA group during the intraoperative period, together with significantly less disrhythmia, less need for inotropic agent and less need for transfusion during the period after the CPB before the patient’s transfer to ICU. These findings are in agreement with the previous reports and suggest that more stable hemodynamic conditions can be provided by HTEA [1,5].

Kessler et al. [14] detected higher MAP measurements in the postoperative ICU in the general anesthesia group. In the present study, we found higher postoperative MAP values in the control group. Less hypertension seen in the HTEA group during the postoperative ICU period may be explained by the efficient pain control and sympatholitic effects of HTEA.

Early extubation has potential benefits such as decrease in intubation-related complications, fast normalization of cilia functions, early recovery of coughing reflex, less pulmonary atelectasis development, significant improvement in intrapulmonary shunt fraction and elimination of disadvantages like deterioration of venous return, decrease in cardiac flow [26]. Numerous studies have previously reported that HTEA decreases the duration of intubation [20,21,27–29]. Similarly, the present study revealed shorter intubation time in the HTEA group. Furthermore, pulmonary compliance measurement which is considered as a marker of postoperative lung functions was similar in the study groups. This finding may be due to the similarities in the duration of cardiopulmonary bypass and surgery.

Requirement for additional analgesics or methods as well as nausea and vomiting were also significantly less in the HTEA group. The segment where epidural catheter was placed and the type and volume of the local anesthetic agent used may explain these findings [14,20,21,23]. The VAS was also less in the HTEA group, whereas the control group revealed smaller VAS value only 12-hour after surgery. The requirement for additional postoperative analgesics was significantly more in the control group. The fast and efficient analgesia provided in the HTEA group explains this difference between the study groups.
Despite that HTEA has been reported to have no superiority in terms of stay in ICU [14], there are studies revealing less stay in ICU and hospital in the HTEA group than the systemic opioid group [15,27]. In the present study, mean duration of stay in ICU as well as hospital was significantly shorter in the HTEA group. These findings suggest that the quality of analgesia provided by HTEA enables early recovery of pulmonary functions without suppressing protective reflexes such as coughing and deep breath. Eventually, hospitalization becomes shorter by early mobilization of patients.

Conclusions

As a conclusion, HTEA may be suggested to improve the balance between oxygen presentation and usage by suppressing neuroendocrine stress response, provide efficient postoperative analgesia, more stable hemodynamic and respiratory conditions, and finally lower the duration of stay in ICU and in hospital after early extubation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References:

1. Scott NB, Turfrey DI, Ray DAA et al: A prospective randomized study of the potential benefits of thoracic epidural anesthesia and analgesia in patients undergoing coronary artery bypass grafting. Anesth Analg, 2001; 93: 528–35
2. Crescenzi G, Landoni G, Monaco F et al: Epidural anesthesia in elderly patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth, 2009; 23: 807–12
3. Ganapathy S, Murkin JM, Dobkowski W, Boyd D: Stress and inflammatory response after beating heart surgery versus conventional bypass surgery: The role of thoracic epidural anesthesia. Heart Surg Forum, 2001; 4: 323–27
4. Kirnö K, Friberg P, Grzegorczyk A et al: Thoracic epidural anesthesia during coronary artery bypass surgery: Effects on cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics. Anesth Analg, 1994; 79: 1075–81
5. Salvi L, Parolari A, Veglia F et al: High thoracic epidural anesthesia in coronary artery bypass surgery: a propensity-matched study. J Cardiothorac Vasc Anesth, 2007; 21: 810–15
6. Tuman KJ, Mc Carty Rl, March Rl et al: Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. Anesth Analg, 1991; 73: 696–704
7. Blomberg S, Emanuelsson H, Kvist H et al: Effects of thoracic epidural anesthesia on coronary arteries and arterioles in patients with coronary artery disease. Anesthesiology, 1990; 73: 840–47
8. Lorentzen AG, Lindskov C, Sloth E, Jakobsen CJ: Central venous oxygen saturation cannot replace mixed venous saturation in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth, 2008; 22: 85–57
9. Gimenes C, De Godoy I, Padovani CR et al: Respiratory pressure and expiratory peak flow rate of patients undergoing coronary artery bypass graft surgery. Med Sci Monit, 2012; 18(9): CR558–63
10. Stenseth R, Bjella L, Berg EM et al: Effects of thoracic epidural analgesia on pulmonary function after coronary artery bypass surgery. Eur J Cardiothorac Surg, 1996; 10: 859–65
11. Meissner A, Rolf N, Van Aken H: Thoracic epidural anesthesia and the patient with heart disease: benefits, risks, and controversies. Anesth Analg, 1997; 85: 517–28
12. Borgardt SF, Sue D’Y (eds.): Current Critical Care Diagnosis and Treatment. New York: McGraw-Hill, 2003: 204–28
13. Goldstein S, Dean D, Kim SJ et al: A survey of spinal and epidural techniques in adult cardiac surgery. J V Cardiothorac Vasc Anesth, 2001; 15: 158–68
14. Kessler P, Aybek T, Neidhart G et al: Comparison of three anesthetic techniques for off-pump coronary artery bypass grafting: general anesthesia, combined general and high thoracic epidural anesthesia, or high thoracic epidural anesthesia alone. J Cardiothorac Vasc Anesth, 2005; 19: 32–39
15. De Leon-Casasola OA, Parker BM, Lema MI et al: Epidural analgesia versus intravenous patient-controlled analgesia. Differences in the postoperative course of cancer patients. Reg Anesth, 1994; 19: 307–15
16. Mangano DT: Perioperative cardiac morbidity. Can J Anaesth, 1994; 41: 13–16
17. Mangano DT, Browner WS, Hollenberg M et al: Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The study of perioperative ischemia research group. N Engl J Med, 1990; 323: 1781–88
18. Bettle WS, Badner NH, Choi P: Epidural analgesia reduces perioperative myocardial infarction. A meta-analysis. Anesth Analg, 2001; 93: 853–58
19. Wheatley RG, Schug SA, Watson D: Safety and efficacy of postoperative epidural analgesia. Br J Anaesth, 2001; 87: 47–61
20. Giebler RM, Scherer RJ, Peters I: Incidence of neurologic complications related to thoracic epidural catheterization. Anesthesiology, 1997; 86: 55–63
21. Bromage PR: Neurological complications of subarachnoid and epidural anesthesia. Acta Anaesthesiol Scand, 1997; 41: 439–44
22. Loick HM, Schmidt C, Van Aken H et al: High thoracic epidural anesthesia, but not clonidine, attenuates the perioperative stress response via sympathetic and reduces the release of troponin T in patients undergoing coronary artery bypass grafting. Anesth Analg, 1999; 88: 701–9
23. Berendes E, Schmidt C, Van Aken H et al: Reversible cardiac sympathetico-my by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting: A randomized trial. Arc Surg, 2003; 138: 1283–90
24. Fillingner MP, Yeager MP, Dodds TM et al: Epidural anesthesia and analgesia: effects on recovery from cardiac surgery. J Cardiothorac Vasc Anesth, 2002; 16: 15–20
25. Mendez-Tellez PA: Cardiopulmonary effects of high thoracic epidural anesthesia. Techniques in regional anesthesia and pain management. 1998; 2: 56–66
26. Knapk M, Knapk P, Nadzkialewicz P et al: Comparison of remifentanil or fentanyl administration during isoflurane anesthesia for coronary artery bypass surgery. Med Sci Monit, 2006; 12(8): PI133–38
27. Lequeux PY, Bouckaert Y, Ssekat H et al: Continuous mixed venous and central venous oxygen saturation in cardiac surgery with cardiopulmonary bypass. Eur J Anaesthesiol, 2010; 27: 291–99
28. Breivik H, Bang U, Jalonen J et al: Nordic guidelines for neuroaxial blocks in disturbed homeostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand, 2010; 54: 16–41
29. Ong CK, Lirk P, Seymour RA, Jenkins BJ: The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg, 2005; 100: 727–73